{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:26:17Z","timestamp":1762104377006,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"am","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.bulcan.2023.07.010","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T09:29:21Z","timestamp":1694251761000},"page":"1251-1259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advanced practice nurse management in multiple myeloma treated with oral therapy"],"prefix":"10.1016","volume":"110","author":[{"given":"Manon","family":"Sapet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Migala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Daguenet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Collet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karima","family":"Boussoualim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Guyotat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Augeul-Meunier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2023.07.010_bib0180","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.6004\/jnccn.2019.0049","article-title":"NCCN guidelines insights: multiple myeloma, version 1.2020","volume":"17","author":"Kumar","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0185","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0190","unstructured":"Les cancers en France en 2018\u00a0\u2013\u00a0l\u2019essentiel des faits et chiffres (\u00e9dition 2019)\u00a0\u2013\u00a0Ref\u00a0: ETKAFR19 n.d. https:\/\/www.e-cancer.fr\/Expertises-et-publications\/Catalogue-des-publications\/Les-cancers-en-France-en-2018-L-essentiel-des-faits-et-chiffres-edition-2019."},{"key":"10.1016\/j.bulcan.2023.07.010_bib0195","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13083","article-title":"Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival","volume":"101","author":"Turesson","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0200","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0205","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0210","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0215","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0220","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0225","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0230","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/asheducation-2017.1.508","article-title":"Management of multiple myeloma in the relapsed\/refractory patient","volume":"2017","author":"Sonneveld","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0235","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0240","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2141.2009.07728.x","article-title":"Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma","volume":"146","author":"Chen","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0245","first-page":"34","article-title":"Analyzing trends in oral anticancer agents in an academic medical facility","volume":"5","author":"Gustafson","year":"2015","journal-title":"J Hematol Oncol Pharm."},{"key":"10.1016\/j.bulcan.2023.07.010_bib0250","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1188\/15.S1.CJON.37-40","article-title":"Overview of the challenges related to oral agents for cancer and their impact on adherence","volume":"19","author":"Tipton","year":"2015","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0255","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.clml.2017.02.024","article-title":"Treating multiple myeloma patients with oral therapies","volume":"17","author":"Kumar","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0260","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/NCC.0b013e3182551587","article-title":"An intervention to improve adherence and management of symptoms for patients prescribed oral chemotherapy agents: an exploratory study","volume":"36","author":"Spoelstra","year":"2013","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0265","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/jan.12828","article-title":"A trial examining an advanced practice nurse intervention to promote medication adherence and symptom management in adult cancer patients prescribed oral anti-cancer agents: study protocol","volume":"72","author":"Spoelstra","year":"2016","journal-title":"J Adv Nurs"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0270","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4103\/apjon.apjon_35_17","article-title":"The effect of structured education to patients receiving oral agents for cancer treatment on medication adherence and self-efficacy","volume":"4","author":"Tokdemir","year":"2017","journal-title":"Asia Pac J Oncol Nurs"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0275","series-title":"Nurses in Advanced Roles: A Description and Evaluation of Experiences in 12 Developed Countries. Documents de travail de l\u2019OCDE sur la sant\u00e9","volume":"4","author":"Delamaire","year":"2010"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0280","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1365-2648.2004.03235.x","article-title":"A framework for the introduction and evaluation of advanced practice nursing roles","volume":"48","author":"Bryant-Lukosius","year":"2004","journal-title":"J Adv Nurs"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0285","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1200\/JOP.2015.007260","article-title":"Improving the safety of oral chemotherapy at an academic medical center","volume":"12","author":"Shah","year":"2016","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0290","unstructured":"Institut national du cancer. Plan cancer 2014\u20132019\u00a0: priorit\u00e9s et objectifs\u00a0\u2013\u00a0plan cancer n.d. https:\/\/www.e-cancer.fr\/Plan-cancer\/Plan-cancer-2014-2019-priorites-et-objectifs."},{"key":"10.1016\/j.bulcan.2023.07.010_bib0295","unstructured":"D\u00e9cret no\u00a02018-629 du 18 juillet 2018 relatif \u00e0 l\u2019exercice infirmier en pratique avanc\u00e9e\u00a0\u2013\u00a0l\u00e9gifrance n.d. https:\/\/www.legifrance.gouv.fr\/loda\/id\/JORFTEXT000037218115\/."},{"key":"10.1016\/j.bulcan.2023.07.010_bib0300","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0305","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12912-016-0130-1","article-title":"Effects of a nurse-led medication self-management programme in cancer patients: protocol for a mixed-method randomised controlled trial","volume":"15","author":"Komatsu","year":"2016","journal-title":"BMC Nurs"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0310","doi-asserted-by":"crossref","first-page":"e006699","DOI":"10.1136\/bmjopen-2014-006699","article-title":"Inner conflict in patients receiving oral anticancer agents: a qualitative study","volume":"5","author":"Yagasaki","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0315","first-page":"4257","article-title":"Jacquin J-P, et al. Effectiveness of a nurse-led telephone follow-up in the therapeutic management of patients receiving oral antineoplastic agents: a randomized, multicenter controlled trial (ETICCO study)","volume":"29","author":"Bouleftour","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0320","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1188\/10.CJON.447-453","article-title":"Perceptions and experiences of patients receiving oral chemotherapy","volume":"14","author":"Simchowitz","year":"2010","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0325","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3109\/0284186X.2015.1119307","article-title":"Adherence to oral anticancer agents: healthcare providers\u2019 perceptions, beliefs and shared decision making in Belgium and the Netherlands","volume":"55","author":"Verbrugghe","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0330","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0335","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1365-2648.2008.04927.x","article-title":"Nurse-led vs. conventional physician-led follow-up for patients with cancer: systematic review","volume":"65","author":"Lewis","year":"2009","journal-title":"J Adv Nurs"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0340","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/bmj.325.7373.1145","article-title":"Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial","volume":"325","author":"Moore","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0345","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ejon.2015.05.009","article-title":"The role of advanced nursing in lung cancer: a framework based development","volume":"19","author":"Serena","year":"2015","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.bulcan.2023.07.010_bib0350","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ejca.2013.11.012","article-title":"Policy statement on multidisciplinary cancer care","volume":"50","author":"Borras","year":"2014","journal-title":"Eur J Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123003466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455123003466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T17:20:38Z","timestamp":1762104038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455123003466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0007455123003466"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.07.010","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced practice nurse management in multiple myeloma treated with oral therapy","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2023.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}